Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy

Journal of Clinical Oncology

Volumn 33, Issue 8, 2015, Pages 944-951

  Den, Robert B ^a   Yousefi, Kasra ^c   Trabulsi, Edouard J ^a   Abdollah, Firas ^b   Choeurng, Voleak ^c   Feng, Felix Y ^c   Dicker, Adam P ^a   Lallas, Costas D ^a   Gomella, Leonard G ^a   Davicioni, Elai ^c   Karnes, R Jeffrey ^d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; SEMINAL VESICLE; ADJUVANT RADIOTHERAPY; ALGORITHM; CLINICAL TRIAL; COHORT ANALYSIS; DECISION MAKING; DNA MICROARRAY; GENETICS; GENOMICS; INCIDENCE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NOMOGRAM; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; ALGORITHMS; BIOMARKERS, TUMOR; COHORT STUDIES; COMBINED MODALITY THERAPY; DECISION MAKING; GENOMICS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NOMOGRAMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; REGRESSION ANALYSIS; RISK ASSESSMENT; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84924975707     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.0026     Document Type: Article

References (46)

1. Silberstein JL, Vickers AJ, Power NE, et al: Reverse stage shift at a tertiary care center: Escalating risk in men undergoing radical prostatectomy. Cancer 117:4855-4860, 2011
2. Cary KC, Paciorek A, Fuldeore MJ, et al: Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: An analysis from the CaPSURE registry. Cancer 120:507-512, 2014
3. Ost P, De Troyer B, Fonteyne V, et al: A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 80:1316-1322, 2011
4. Trabulsi EJ, Valicenti RK, Hanlon AL, et al: A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 72:1298-1302, 2008
5. Briganti A, Wiegel T, Joniau S, et al: Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: Results of a match-controlled multi-institutional analysis. Eur Urol 62:472-487, 2012
6. Parker C, Clarke N, Logue J, et al: RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol) 19:167-171, 2007
7. Richaud P, Sargos P, Henriques de Figueiredo B, et al: Postoperative radiotherapy of prostate cancer. Cancer Radiother 14:500-503, 2010
8. Pearse M, Fraser-Browne C, Davis ID, et al: A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: Background and rationale of the Radiotherapy-Adjuvant Versus Early Salvage (RAVES) trial. BJU Int 113:7-12, 2014 (suppl)
9. Den RB, Feng FY, Showalter TN, et al: Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 89:1038-1046, 2014
10. Karnes RJ, Bergstralh EJ, Davicioni E, et al: Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 190:2047-2053, 2013
11. Mishra MV, Scher ED, Andrel J, et al: Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes. Am J Clin Oncol [epub ahead of print on March 26, 2013]
12. Briganti A, Karnes RJ, Joniau S, et al: Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 66:479-486, 2014
13. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 100:229-235, 2006
14. Lockstone HE: Exon array data analysis using Affymetrix power tools and R statistical software. Brief Bioinform 12:634-644, 2011
15. Piccolo SR, Sun Y, Campbell JD, et al: A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics 100:337-344, 2012
16. Erho N, Crisan A, Vergara IA, et al: Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 8:e66855, 2013
17. Cooperberg MR, Hilton JF, Carroll PR: The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117:5039-5046, 2011
18. Stephenson AJ, Scardino PT, Eastham JA, et al: Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23:7005-7012, 2005
19. Heagerty PJ, Lumley T, Pepe MS: Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56:337-344, 2000
20. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
21. Tibshirani R: The lasso method for variable selection in the Cox model. Stat Med 16:385-395, 1997
22. Firth D: Bias reduction of maximum likelihood estimates. Biometrika 80:27, 1993
23. Vickers AJ, Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 26:565-574, 2006
24. Swanson GP, Hussey MA, Tangen CM, et al: Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25:2225-2229, 2007
25. Thompson IM Jr, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296:2329-2335, 2006
26. Thompson IM, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. J Urol 181:956-962, 2009
27. Bolla M, van Poppel H, Collette L, et al: Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366:572-578, 2005
28. Bolla M, van Poppel H, Tombal B, et al: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018-2027, 2012
29. Wiegel T, Bottke D, Steiner U, et al: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924-2930, 2009
30. Wiegel T, Bartkowiak D, Bottke D, et al: Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 66:243-250, 2014
31. Daly T, Hickey BE, Lehman M, et al: Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev 12:CD007234, 2011
32. Thompson IM, Valicenti RK, Albertsen P, et al: Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 190:441-449, 2013
33. Stephenson AJ, Bolla M, Briganti A, et al: Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 61:443-451, 2012
34. Thompson IM, Tangen CM, Klein EA: Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol 27:2898-2899, 2009
35. Widmark A, Klepp O, Solberg A, et al: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 373:301-308, 2009
36. Warde P, Mason M, Ding K, et al: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 378:2104-2111, 2011
37. Shariat SF, Kattan MW, Vickers AJ, et al: Critical review of prostate cancer predictive tools. Future Oncol 5:1555-1584, 2009
38. Punnen S, Freedland SJ, Presti JC Jr, et al: Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol 65:1171-1177, 2014
39. Sheets NC, Hendrix LH, Allen IM, et al: Trends in the use of postprostatectomy therapies for patients with prostate cancer: A Surveillance, Epidemiology, and End Results Medicare analysis. Cancer 119:3295-3301, 2013
40. Schreiber D, Rineer J, Yu JB, et al: Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer 116:5757-5766, 2010
41. Kalbasi A, Swisher-McClure S, Mitra N, et al: Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer 120:3089-3096, 2014
42. Ghia AJ, Shrieve DC, Tward JD: Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: Postprostatectomy adjuvant radiotherapy - A SEER analysis. Urology 76:1169-1174, 2010
43. Hoffman KE, Nguyen PL, Chen MH, et al: Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 185:116-120, 2011
44. Abernethy AP, Etheredge LM, Ganz PA, et al: Rapid-learning system for cancer care. J Clin Oncol 28:4268-4274, 2010
45. Pepe MS, Feng Z, Janes H, et al: Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. J Natl Cancer Inst 100:1432-1438, 2008
46. Wilson LS, Tesoro R, Elkin EP, et al: Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109:518-527, 2007